PL2431741T3 - Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) - Google Patents
Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)Info
- Publication number
- PL2431741T3 PL2431741T3 PL11009919T PL11009919T PL2431741T3 PL 2431741 T3 PL2431741 T3 PL 2431741T3 PL 11009919 T PL11009919 T PL 11009919T PL 11009919 T PL11009919 T PL 11009919T PL 2431741 T3 PL2431741 T3 PL 2431741T3
- Authority
- PL
- Poland
- Prior art keywords
- peg
- pegylation
- vitro
- pro
- methods
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10725708P | 2008-10-21 | 2008-10-21 | |
| US24263409P | 2009-09-15 | 2009-09-15 | |
| EP09752561A EP2350658A2 (en) | 2008-10-21 | 2009-10-20 | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| EP11009919.9A EP2431741B1 (en) | 2008-10-21 | 2009-10-20 | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2431741T3 true PL2431741T3 (pl) | 2014-01-31 |
Family
ID=41507861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11009919T PL2431741T3 (pl) | 2008-10-21 | 2009-10-20 | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9274122B2 (pl) |
| EP (2) | EP2431741B1 (pl) |
| JP (1) | JP5775820B2 (pl) |
| AU (1) | AU2009307729B2 (pl) |
| CA (1) | CA2740904C (pl) |
| DK (1) | DK2431741T3 (pl) |
| PL (1) | PL2431741T3 (pl) |
| WO (1) | WO2010048184A2 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2893605T3 (es) * | 2011-05-18 | 2022-02-09 | Takeda Pharmaceuticals Co | Ensayos de actividad dependientes de modificación |
| WO2013138730A1 (en) * | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| JP7407511B2 (ja) | 2015-10-08 | 2024-01-04 | ネクター セラピューティクス | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 |
| CN119700941A (zh) | 2017-05-15 | 2025-03-28 | 尼克塔治疗公司 | 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 |
| ES3020087T3 (en) | 2020-09-21 | 2025-05-21 | Instr Laboratory Co | Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US7074878B1 (en) * | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US20040022792A1 (en) * | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| US20050276823A1 (en) * | 2002-07-12 | 2005-12-15 | Cini John K | Methods and compositions for preventing oxidative degradation of proteins |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CA2507904C (en) * | 2002-12-19 | 2014-12-02 | M. Elizabeth Snell | Cyanovirin variant-polymer conjugates |
| CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| CN1812808B (zh) * | 2003-06-03 | 2012-07-04 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
| DK1835938T3 (da) * | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| HUE025208T2 (en) * | 2005-06-16 | 2016-03-29 | Nektar Therapeutics | Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates |
| WO2007025988A2 (en) * | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| US8133865B2 (en) * | 2006-12-27 | 2012-03-13 | Nektar Therapeutics | von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage |
-
2009
- 2009-10-20 PL PL11009919T patent/PL2431741T3/pl unknown
- 2009-10-20 US US12/582,497 patent/US9274122B2/en active Active
- 2009-10-20 EP EP11009919.9A patent/EP2431741B1/en active Active
- 2009-10-20 AU AU2009307729A patent/AU2009307729B2/en active Active
- 2009-10-20 JP JP2011532331A patent/JP5775820B2/ja active Active
- 2009-10-20 WO PCT/US2009/061327 patent/WO2010048184A2/en not_active Ceased
- 2009-10-20 CA CA2740904A patent/CA2740904C/en active Active
- 2009-10-20 DK DK11009919.9T patent/DK2431741T3/da active
- 2009-10-20 EP EP09752561A patent/EP2350658A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2350658A2 (en) | 2011-08-03 |
| AU2009307729A1 (en) | 2010-04-29 |
| AU2009307729B2 (en) | 2015-09-17 |
| WO2010048184A3 (en) | 2010-06-17 |
| US9274122B2 (en) | 2016-03-01 |
| EP2431741B1 (en) | 2013-08-21 |
| EP2431741A1 (en) | 2012-03-21 |
| DK2431741T3 (da) | 2013-10-21 |
| JP5775820B2 (ja) | 2015-09-09 |
| CA2740904A1 (en) | 2010-04-29 |
| JP2012506382A (ja) | 2012-03-15 |
| WO2010048184A2 (en) | 2010-04-29 |
| CA2740904C (en) | 2019-01-15 |
| US20100112607A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180934T1 (hr) | Optimizirani sustav unosa in vivo s endosomolitičkim sredstvima za konjugate nukleinskih kiselina | |
| BRPI0917000A2 (pt) | proteínas conjugadas com eficácia in vivo prolongada | |
| EP1972269B8 (de) | System zur in-vivo Messung einer Analytkonzentration | |
| IL194438A (en) | Diarrhylthiohydantoin Compounds, Pharmaceuticals Containing Them, Syntheses Methods and In Vitro Methods for Contacting them with Mammalian Cells | |
| EP3460064B8 (en) | Efficient protein expression in vivo using modified rna (mod-rna) | |
| DK2268317T3 (da) | Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme | |
| IL195839A0 (en) | New protein conjugates and methods for their preparation | |
| SI1972275T1 (sl) | Sistem za merjenje koncentracije analita in vivo | |
| BRPI1009829A2 (pt) | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos | |
| ZA201103669B (en) | Peptide derivatives and use thereof as carriers for molecules in the form of conjugates | |
| GB0815264D0 (en) | Non-cytotoxic proteins | |
| IL191064A0 (en) | Real time nucleic acid detection in vivo using protein complementation | |
| PL2431741T3 (pl) | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) | |
| GB2462761B (en) | Protein formulation | |
| IL194940A0 (en) | Protein assay | |
| IL205237A0 (en) | Nucleic acid complex and nucleic acid delivery composition | |
| DE602007011518D1 (de) | Stabilisator für In-vivo-Untersuchungen | |
| GB0808086D0 (en) | Magnetic proteins for in vivo imaging | |
| EP1960531A4 (en) | PROTOCOL FOR DETECTING A PROTEIN IN A CULTURE WITH AN EMBRYO | |
| GB0620200D0 (en) | Conjugates for use in analyte detection | |
| EP2356238A4 (en) | NURR1 INTERACTIVE PROTEIN (NUIP) | |
| GB2458016B (en) | Protein probe, compositions and methods | |
| GB0704356D0 (en) | DNA damage and amino acid metabolism in the early embryo | |
| PL385446A1 (pl) | Sonda do pomiaru wilgotności, zwłaszcza elementów o zakrzywionych powierzchniach | |
| HK1151477A (en) | Compositions and methods for tissue-specific rnai delivery in vivo |